Are You a Candidate? Current Eligibility Criteria

If someone told you that you need a BMI of 40, or 35 with a comorbidity, they were quoting a document written in 1991. If they added that you have to be between 18 and 60, that age range is not in the 1991 statement at all, it is a habit that grew up around it. That guidance stood for over three decades and it no longer represents the standard of care. Whether your insurer knows that is a separate question, and an important one.

What the old criteria said

The 1991 National Institutes of Health consensus statement set the framework that everything since has been measured against. It said that patients whose BMI exceeds 40 are potential candidates for surgery, and that in certain instances patients with a BMI between 35 and 40 may also be considered, specifically those with high risk comorbid conditions such as severe sleep apnea, obesity related cardiomyopathy or severe diabetes, or with obesity induced physical problems interfering with lifestyle. On young people it was explicit: children and adolescents had not been sufficiently studied to allow a recommendation, even with a BMI over 40.

That was a reasonable summary of the evidence in 1991. Thirty years of data followed.

What the 2022 guidelines say

The joint ASMBS and IFSO indications for metabolic and bariatric surgery, published in 2022, changed the thresholds substantially.

• BMI 35 and above. Surgery is recommended for individuals with a BMI of 35 or higher, regardless of the presence, absence or severity of comorbidities. You no longer need a second diagnosis to qualify clinically.
• BMI 30 to 34.9. Surgery should be considered for individuals with metabolic disease who have not succeeded with nonsurgical treatment.
• Type 2 diabetes. Surgery is recommended for patients with type 2 diabetes and a BMI of 30.
• Asian populations. Clinical obesity is recognized from a BMI of 25, and the guideline says surgery should be offered from a BMI of 27.5. The guideline states that access to surgery should not be denied solely on the basis of traditional BMI risk zones.
• Older adults. There is no evidence to support an upper age limit. Selection should include assessment of frailty rather than relying on chronological age.
• Adolescents. Surgery should be considered for children and adolescents with a BMI above 120 percent of the 95th percentile, which is class II obesity, together with a major comorbidity, or above 140 percent of the 95th percentile, which is class III obesity, regardless of comorbidity. Surgery does not negatively affect pubertal development or linear growth.

The guideline also addresses some of the barriers patients run into. On adolescents, it notes that syndromic obesity, developmental delay, autism spectrum diagnoses and a history of trauma are increasingly not considered contraindications. On preoperative requirements, it states that there are no data to support the practice of insurance mandated preoperative weight loss, and describes that practice as discriminatory, arbitrary and scientifically unfounded. If you have been told to complete six months of supervised dieting before you can be approved, that requirement is a payer policy, not a clinical standard.

What the guideline does support is multidisciplinary evaluation, including medical, surgical, psychiatric and nutritional expertise, with nutritional assessment by a registered dietitian.

What genuinely rules someone out

The list of true contraindications is shorter than most people expect, and it does not include being scared, being older, having failed diets before, or having a low pain tolerance. For gastric bypass, absolute contraindications are described as pregnancy, inability to tolerate general anesthesia, and severe incapacitating systemic disease including end stage renal disease, unstable coronary artery disease, severe heart failure, cirrhosis with portal hypertension, and active malignancy.

Relative contraindications, meaning things that need to be addressed rather than things that end the conversation, include:

• Active inflammatory disease of the gastrointestinal tract, including ulcers, severe esophagitis and Crohn disease
• Uncontrolled and untreated psychiatric illness, including active psychosis, substance and alcohol use disorders, and recent suicide attempts
• Conditions carrying bleeding risk in the esophagus or stomach, such as varices
• Chronic long term steroid treatment
• Active infection
• Epilepsy, because absorption of antiseizure medication changes after bypass and needs planning with your neurologist and pharmacist

Several conditions that sound disqualifying are not. The 2022 guideline notes that patients with compensated cirrhosis face higher perioperative mortality but that the risk remains under 1 percent while the benefits are significant, that surgery can be a useful adjunct in patients with heart failure before transplant or placement of a left ventricular assist device, and that it has been used in end stage organ disease to improve transplant candidacy. These are complex cases handled at experienced centers, not automatic refusals.

The gap between eligible and covered

Meeting the clinical criteria and getting a payer to write a check are two different processes. The Medicare national coverage determination for bariatric surgery still requires a BMI of 35 or higher, at least one comorbidity related to obesity, and previous unsuccessful medical treatment for obesity. Type 2 diabetes has counted as a qualifying comorbidity since 2009. Sleeve gastrectomy is covered at the discretion of Medicare Administrative Contractors under those same three conditions, a policy in place since June 2012. Treatment of obesity alone remains non covered.

Line that up against the 2022 guideline and the mismatch is obvious. A person with a BMI of 36 and no other diagnosis is recommended for surgery by ASMBS and IFSO and does not meet the Medicare comorbidity requirement. A person with a BMI of 32 and type 2 diabetes is recommended by the guideline and falls below the Medicare BMI threshold entirely. A person of Asian descent with a BMI of 29 and metabolic disease is squarely outside every coverage rule written around a threshold of 35.

A few other details are worth knowing. The requirement that surgery be performed at a specially certified facility was dropped for dates of service on and after September 24, 2013, so the old center of excellence designations no longer control coverage. Coverage decisions for procedures not specifically named in the national determination, which includes SADI-S, are left to local contractors. Private insurance policies vary widely and set their own documentation, supervised diet and psychological evaluation requirements.

The practical consequence is that your eligibility conversation happens twice, once with your surgical team about what is medically appropriate and once with your insurer about what they will authorize. Those two conversations can reach different answers, and the appeals process exists for exactly that reason. Be patient and persistent. You might be on hold, you might get a rude representative, and you might get an answer that you are sure is wrong. Take a deep breath and try again.

Where GLP-1 medications fit

The medications have changed the landscape without changing the surgical criteria. In a real world analysis of nearly 20 million patients presented at the 2026 ASMBS annual meeting, GLP-1 prescriptions grew from fewer than 4,600 in 2018 to more than 1.4 million in 2025. Bariatric procedures in the same dataset rose from just under 20,000 in 2018 to almost 43,000 in 2023, then fell in 2024 and 2025 to under 40,000. Throughout, the share of people with severe obesity receiving no treatment at all stayed between 90 and 95 percent. The researchers noted that the decline in surgery may be concentrated among patients with the highest degrees of obesity and disease severity, which is the group most likely to benefit from an operation.

If you have taken a GLP-1 and are wondering whether you have missed your window, the current evidence says no. A study of more than 6,700 patients prescribed GLP-1 medications in the six months before surgery found they lost about 8 percent of total body weight on medication beforehand, then reached more than 25 percent total weight loss after gastric bypass and about 20 percent after sleeve gastrectomy. Patients who went straight to surgery lost about 2 to 3 percent more from the operation itself, meaning prior medication use did little to reduce surgical effectiveness. Patients who had used GLP-1s beforehand were more likely to resume them afterward, with about two thirds back on medication by three years.

What has not happened is a formal change in which operation you should be offered based on GLP-1 use. The 2022 indications remain the standard. How medication and surgery sequence together in your case is a decision for you and your prescriber and surgeon.

The number that should bother you

ASMBS estimates that less than 1 percent of people who meet the eligibility requirements have surgery in any given year. More than 270,000 procedures were performed in 2023, against a population of eligible people in the tens of millions. Whatever has kept you from having this conversation, you are in the overwhelming majority, and being in the majority is not the same as being right.